UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 864

Sortiert nach

Measuring financial toxicity as a clinically relevant patient‐reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST)

Cancer, 2017-02, Vol.123 (3), p.476-484

2017

Volltextzugriff (PDF)

The development of a financial toxicity patient‐reported outcome in cancer: The COST measure

Cancer, 2014-10, Vol.120 (20), p.3245-3253

2014

Volltextzugriff (PDF)

Economic Analyses in Squamous Cell Carcinoma of the Head and Neck: A Review of the Literature From a Clinical Perspective

International journal of radiation oncology, biology, physics, 2014-08, Vol.89 (5), p.989-996

2014

Volltextzugriff (PDF)

Thyroid cancer: burden of illness and management of disease

Journal of Cancer, 2011-01, Vol.2 (1), p.193-199

2011

Volltextzugriff (PDF)

Global Health Equity: Cancer Care Outcome Disparities in High-, Middle-, and Low-Income Countries

Journal of clinical oncology, 2016-01, Vol.34 (1), p.6-13

2016

Volltextzugriff (PDF)

A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Clinical cancer research, 2012-04, Vol.18 (8), p.2336-2343

2012

Volltextzugriff (PDF)

Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial

Journal of clinical oncology, 2017-10, Vol.35 (29), p.3315-3321

2017

Volltextzugriff (PDF)

Role of molecular markers in the management of head and neck cancers

Current opinion in oncology, 2011-05, Vol.23 (3), p.259-264

2011

Volltextzugriff (PDF)

Access to cancer medications in low- and middle-income countries

Nature reviews. Clinical oncology, 2013-06, Vol.10 (6), p.314-322

2013

Volltextzugriff (PDF)

Unsupported off-label chemotherapy in metastatic colon cancer

BMC health services research, 2012-12, Vol.12 (1), p.481-481, Article 481

2012

Volltextzugriff (PDF)

User beware: we need more science and less art when measuring financial toxicity in oncology

Journal of clinical oncology, 2015-04, Vol.33 (12), p.1414-1415

2015

Volltextzugriff (PDF)

Mitigating Financial Toxicity Among US Patients With Cancer

JAMA oncology, 2017-06, Vol.3 (6), p.765

2017

Volltextzugriff (PDF)

A phase I trial adding poly(ADP-ribose) polymerase inhibitor veliparib to induction carboplatin-paclitaxel in patients with head and neck squamous cell carcinoma: Alliance A091101

Oral oncology, 2021-03, Vol.114, p.105171-105171, Article 105171

2021

Volltextzugriff (PDF)

State insurance mandates and off‐label use of chemotherapy

Health economics, 2018-01, Vol.27 (1), p.e55-e70

2018

Volltextzugriff (PDF)

CYP2D6 Genotyping and Tamoxifen: An Unfinished Story in the Quest for Personalized Medicine

Seminars in oncology, 2011-04, Vol.38 (2), p.263-273

2011

Volltextzugriff (PDF)

Financial toxicity in cancer care

The Journal of community and supportive oncology, 2016-03, Vol.14 (3), p.101-106

2016

Volltextzugriff (PDF)

The Future of Cancer Care: Are We Ready For Personalized Value?

Journal of the National Comprehensive Cancer Network, 2015-08, Vol.13 (8), p.1049

2015

Volltextzugriff (PDF)

Value-based insurance design: aligning incentives, benefits, and evidence in oncology

Journal of the National Comprehensive Cancer Network, 2012-01, Vol.10 (1), p.18

2012

Volltextzugriff (PDF)

The cost of cancer care: there is more than one elephant in the room

Oncology (Williston Park, N.Y.), 2012-10, Vol.26 (10), p.926-928

De Souza, Jonas A

2012

Volltextzugriff (PDF)

Grading financial toxicity based upon its impact on health-related quality of life (HRQol)

Journal of clinical oncology, 2016-01, Vol.34 (3_suppl), p.16-16

2016

Volltextzugriff (PDF)

The overlooked COST of multiple myeloma

The Lancet. Haematology, 2015-10, Vol.2 (10), p.e394-e395

2015

Volltextzugriff (PDF)

Results of randomized phase II trial of dabrafenib versus dabrafenib plus trametinib in BRAF-mutated papillary thyroid carcinoma

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.6022-6022

2017

Volltextzugriff (PDF)

The global breast cancer disparity: strategies for bridging the gap

JAMA : the journal of the American Medical Association, 2009-12, Vol.302 (23), p.2589

2009

Volltextzugriff (PDF)

A value framework in head and neck cancer care

American Society of Clinical Oncology educational book, 2014 (34), p.e304-e309

2014

Volltextzugriff (PDF)

[18F]Fluorodeoxyglucose positron emission tomography in the initial staging of squamous cell carcinoma of the head and neck: promise, evidence, and reality

Journal of clinical oncology, 2010-10, Vol.28 (28), p.e516; author reply e517-e516

2010

Volltextzugriff (PDF)

1 – 25 von 864

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(672)
Mit Volltextzugriff
(811)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

4 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(405)
Life Sciences & Biomedicine
(303)
Humans
(109)
Physical Sciences
(71)
Female
(68)
Agriculture
(61)
Technology
(55)
Animals
(48)
Male
(45)
Brazil
(42)
Science & Technology - Other Topics
(42)
Multidisciplinary Sciences
(36)
Plant Sciences
(36)
Chemistry
(34)
Silicon
(32)
Engineering
(31)
Adult
(29)
Oncology
(29)
Environmental Sciences & Ecology
(27)
Biomedical And Life Sciences
(26)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(8)
... seit 90 Tagen
(28)

Menü

Weitere Dienste

Einstellungen

Measuring financial toxicity as a clinically relevant patient‐reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST)

The development of a financial toxicity patient‐reported outcome in cancer: The COST measure

Economic Analyses in Squamous Cell Carcinoma of the Head and Neck: A Review of the Literature From a Clinical Perspective

Thyroid cancer: burden of illness and management of disease

Global Health Equity: Cancer Care Outcome Disparities in High-, Middle-, and Low-Income Countries

A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial

Role of molecular markers in the management of head and neck cancers

Access to cancer medications in low- and middle-income countries

Unsupported off-label chemotherapy in metastatic colon cancer

User beware: we need more science and less art when measuring financial toxicity in oncology

Mitigating Financial Toxicity Among US Patients With Cancer

A phase I trial adding poly(ADP-ribose) polymerase inhibitor veliparib to induction carboplatin-paclitaxel in patients with head and neck squamous cell carcinoma: Alliance A091101

State insurance mandates and off‐label use of chemotherapy

CYP2D6 Genotyping and Tamoxifen: An Unfinished Story in the Quest for Personalized Medicine

Financial toxicity in cancer care

The Future of Cancer Care: Are We Ready For Personalized Value?

Value-based insurance design: aligning incentives, benefits, and evidence in oncology

The cost of cancer care: there is more than one elephant in the room

Grading financial toxicity based upon its impact on health-related quality of life (HRQol)

The overlooked COST of multiple myeloma

Results of randomized phase II trial of dabrafenib versus dabrafenib plus trametinib in BRAF-mutated papillary thyroid carcinoma

The global breast cancer disparity: strategies for bridging the gap

A value framework in head and neck cancer care

[18F]Fluorodeoxyglucose positron emission tomography in the initial staging of squamous cell carcinoma of the head and neck: promise, evidence, and reality

Suchergebnisse filtern